Sophie Borot

Sophie Borot

Auto-generated profile, based on publicly available information

Sophie Borot

Centre Hospitalier Universitaire de Besançon, Besançon, France

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2020 in Diabetologia
Verified
Journal Article
Open access
PDF file
BCBertrand Cariou
Bertrand Cariou
SHSamy Hadjadj
Samy Hadjadj
MWMatthieu Wargny
Matthieu Wargny
MPMatthieu PICHELIN
Matthieu PICHELIN
AAAbdallah Al-Salameh
Abdallah Al-Salameh
FIfor the CORONADO investigators
for the CORONADO investigators
Aims/hypothesis: Coronavirus disease-2019 (COVID-19) is a life-threatening infection caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus. Diabetes has rapidly emerged as a major comorbidity for COVID-19 severity. However, the phenotypic characteristics of diabetes in COVID-19 patients are unknown. Methods: We conducted a nationwide multicentre observational study in people with diabetes hospitalised for COVID-19 in 53 French centres in the period 10–31 March 2020. The primary outcome combined tracheal intubation for mechanical ventilation and/or death within 7 days of admission. Age- and sex-adjusted multivariable logistic regressions were performed to assess the prognostic value of clinical and biological features with the endpoint. ORs are reported for a 1 SD increase after standardisation. Results: The current analysis focused on 1317 participants: 64.9% men, mean age 69.8 ± 13.0 years, median BMI 28.4 (25th–75th percentile: 25.0–32.7) kg/m2; with a predominance of type 2 diabetes (88.5%). Microvascular and macrovascular diabetic complications were found in 46.8% and 40.8% of cases, respectively. The primary outcome was encountered in 29.0% (95% CI 26.6, 31.5) of participants, while 10.6% (9.0, 12.4) died and 18.0% (16.0, 20.2) were discharged on day 7. In univariate analysis, characteristics prior to admission significantly associated with the primary outcome were sex, BMI and previous treatment with renin–angiotensin–aldosterone system (RAAS) blockers, but not age, type of diabetes, HbA1c, diabetic complications or glucose-lowering therapies. In multivariable analyses with covariates prior to admission, only BMI remained positively associated with the primary outcome (OR 1.28 [1.10, 1.47]). On admission, dyspnoea (OR 2.10 [1.31, 3.35]), as well as lymphocyte count (OR 0.67 [0.50, 0.88]), C-reactive protein (OR 1.93 [1.43, 2.59]) and AST (OR 2.23 [1.70, 2.93]) levels were independent predictors of the primary outcome. Finally, age (OR 2.48 [1.74, 3.53]), treated obstructive sleep apnoea (OR 2.80 [1.46, 5.38]), and microvascular (OR 2.14 [1.16, 3.94]) and macrovascular complications (OR 2.54 [1.44, 4.50]) were independently associated with the risk of death on day 7. Conclusions/interpretations: In people with diabetes hospitalised for COVID-19, BMI, but not long-term glucose control, was positively and independently associated with tracheal intubation and/or death within 7 days. Trial registration: clinicaltrials.gov NCT04324736.

1 February 2018 in Diabetes & Metabolism
Verified
Journal Article
Closed access
SBS. Borot
S. Borot
PBP.Y. Benhamou
P.Y. Benhamou
CAC. Atlan
C. Atlan
EBE. Bismuth
E. Bismuth
EBE. Bonnemaison
E. Bonnemaison
HHH. Hanaire
H. Hanaire

7 May 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
SLSandrine Lablanche
Sandrine Lablanche
SBSophie Borot
Sophie Borot
AWAnne Wojtusciszyn
Anne Wojtusciszyn
KSKristina Skaare
Kristina Skaare
APAlfred Penfornis
Alfred Penfornis
TNThe Gragil Network
The Gragil Network
To describe the 10‐year outcomes of islet transplantation within the Swiss‐French GRAGIL Network, in patients with type 1 diabetes experiencing high glucose variability associated with severe hypoglycemia and/or with functional kidney graft. We conducted a retrospective analysis of all subjects transplanted in the GRAGIL‐1c and GARGIL‐2 islet transplantation trials and analyzed components of metabolic control, graft function and safety outcomes over the 10‐year period of follow‐up. Forty‐four patients were included between September 2003 and April 2010. Thirty‐one patients completed a ten‐year follow‐up. Ten years after islet transplantation, median HbA1c was 7.2% [6.2‐8.0] (55 mmol/mol [44‐64]) vs 8.0% [7.1‐9.1] (64 mmol/mol [54‐76]) before transplantation (p<0.001). 17/23 (73.9%) recipients were free of severe hypoglycemia, 1/21 patient (4.8%) was insulin‐independent and median C‐peptide was 0.6 ng/ml [0.2‐1.2]. Insulin requirements (UI/kg/day) were 0.3 [0.1‐0.5] vs 0.5 [0.4‐0.6] before transplantation (p<0.001). Median [IQR] β‐score was 1 [0‐4] (p<0.05 when comparing with pre‐transplantation values) and 51.9% recipients had a functional islet graft at 10 years. With a 10‐year follow up in a multicentric network, islet transplantation provided sustained improvement of glycemic control and was efficient to prevent severe hypoglycemia in almost 75% of the recipients.

30 July 2014 in Journal of Diabetes Science and Technology
Verified
Journal Article
Open access
SBSophie Borot
Sophie Borot
SFSylvia Franc
Sylvia Franc
JCJustine Cristante
Justine Cristante
APAlfred Penfornis
Alfred Penfornis
PBPierre-Yves Benhamou
Pierre-Yves Benhamou
OGon behalf of the Diabeloop Study Group
on behalf of the Diabeloop Study Group
Background: The JewelPUMP™ (JP) is a new patch pump based on a microelectromechanical system that operates without any plunger. The study aimed to evaluate the infusion accuracy of the JP in vitro and in vivo. Methods: For the in vitro studies, commercially available pumps meeting the ISO standard were compared to the JP: the MiniMed® Paradigm® 712 (MP), Accu-Chek® Combo (AC), OmniPod® (OP), Animas® Vibe™ (AN). Pump accuracy was measured over 24 hours using a continuous microweighing method, at 0.1 and 1 IU/h basal rates. The occlusion alarm threshold was measured after a catheter occlusion. The JP, filled with physiological serum, was then tested in 13 patients with type 1 diabetes simultaneously with their own pump for 2 days. The weight difference was used to calculate the infused insulin volume. Results: The JP showed reduced absolute median error rate in vitro over a 15-minute observation window compared to other pumps (1 IU/h): ±1.02% (JP) vs ±1.60% (AN), ±1.66% (AC), ±2.22% (MP), and ±4.63% (OP), P < .0001. But there was no difference over 24 hours. At 0.5 IU/h, the JP was able to detect an occlusion earlier than other pumps: 21 (19; 25) minutes vs 90 (85; 95), 58 (42; 74), and 143 (132; 218) minutes (AN, AC, MP), P < .05 vs AN and MP. In patients, the 24-hour flow error was not significantly different between the JP and usual pumps (–2.2 ± 5.6% vs –0.37 ± 4.0%, P = .25). The JP was found to be easier to wear than conventional pumps. Conclusions: The JP is more precise over a short time period, more sensitive to catheter occlusion, well accepted by patients, and consequently, of potential interest for a closed-loop insulin delivery system.

15 June 2022 in Diabetologia
Verified
Journal Article
Closed access
PDF file
BCBertrand Cariou
Bertrand Cariou
MWMatthieu Wargny
Matthieu Wargny
ABAnne-Sophie Boureau
Anne-Sophie Boureau
SSSarra Smati
Sarra Smati
BTBlandine Tramunt
Blandine Tramunt
OIon behalf of the CORONADO investigators
on behalf of the CORONADO investigators

30 May 2024 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
SLSandrine Lablanche
Sandrine Lablanche
JDJohanna Delagenière
Johanna Delagenière
MJManon Jalbert
Manon Jalbert
ESEmmanuel Sonnet
Emmanuel Sonnet
MBMuriel Benichou
Muriel Benichou
LKLaurence Kessler
Laurence Kessler
Aim: To evaluate the evolution of glycemic outcomes in patients living with type 1 diabetes (T1D) after 1 year of use of the MiniMed 780G advanced hybrid closed-loop (AHCL) system. Methods: We conducted an observational, retrospective, multicentric study in 20 centers in France. The primary objective was to evaluate the improvement in glycemic control after 1-year use of AHCL. The primary endpoint was the variation of time in range (TIR) between pre-AHCL and after 1-year use of AHCL. Secondary objectives were to analyze the glycemic outcomes after 3, 6, and 12 months of AHCL use, the safety, and the long-term observance of AHCL. Results: Two hundred twenty patients were included, and 200 were analyzed for the primary endpoint. 92.7% of patients continued to use AHCL. After 1 year of use of AHCL, TIR was 72.5% ± 10.6% (+9.1%; 95% confidence interval [CI] [7.6–10.5] compared to pre-AHCL initiation, P < 0.001), HbA1c 7.1% ± 0.7% (−0.5%; 95% CI [−0.6 to −0.4]; P < 0.001), time below range 2.0% [1.0; 3.0] (0.0% [−2.0; 0.0], P < 0.001), and time above range 24.8% ± 10.9% (−7.3%; 95% CI [−8.8 to −5.7]; P < 0.001). More patients achieved the glycemic treatment goals of HbA1c <7.0% (45.1% vs. 18.1%, P < 0.001) and TIR >70% (59.0% vs. 29.5% P < 0.001) when compared with pre-AHCL. Five patients experienced severe hypoglycemia events and two patients experienced ketoacidosis. Conclusion: After 1 year of use of AHCL, people living with T1D safely improved their glucose control and a higher proportion of them achieved optimal glycemic control.